Report ID: 10325826 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Global Drug Discovery Services Market By Type (Medicinal Chemistry
Services, Biology Services, Pharmacokinetics and Drug Metabolism), By
Drug Type (Small Molecules, Biologics), By Therapeutic Area (Oncology,
Neurological Disorder, Respiratory Disease, Diabetes, Cardiovascular
Disease), By Regions (North America, Europe, Asia Pacific, Rest of the
World) – Global Forecast up to 2025
This market research report includes a detailed segmentation of the global drug
discovery services market by type (medicinal chemistry services, biology services,
and pharmacokinetics and drug metabolism), by drug type (small molecules and
biologics), by therapeutic area (oncology, neurological disorder, respiratory disease,
diabetes, cardiovascular disease, and others), and by regions (North America,
Europe, Asia Pacific, and Rest of the World).
Overview of the Global Drug Discovery Services Market Research:
Infoholic’s market research report predicts that the global drug discovery services
market will grow at a CAGR of 11.7% during the forecast period 2019–2025. Drug
discovery refers to the process of identifying potential new medicines, and it
involves a wide range of scientific disciplines, including biology, chemistry, and
pharmacology. The process of drug discovery involves various methods such as
identification of target molecule, candidate drug identification, characterization,
screening, and assays for therapeutic efficacy. Once a candidate compound has
shown its therapeutic value in these tests, it will begin the process of drug
development prior to clinical trials. In recent years, there is a lot of interest in
biologics-based drug discovery. Biologics drug discovery includes developing new
novel antibodies, recombinant proteins, hormones, vaccines, cell therapy, and gene
therapy for treating cancer, neurological disorders, cardiovascular disorders, and
many others.
The upsurge in the externalization of R&D activities, rising expenditure on R&D,
expiration of patents boosting the demand for drug discovery, and introduction of
advanced technologies are few of the factors driving the growth of the drug
discovery services market.
Increasing patient base for various chronic & lifestyle diseases and growing
advancements in innovative technologies will enhance the revenue of the drug
discovery services market in the next five years.
•Adventofinnovativetechnology•ExpirationofpatentsbooststhedemandfordrugdiscoveryOpportunities
Risk•Highcostfordiscoveryanddevelopmentofdrugs•Strictregulationsgoverningdrugdiscovery&developmentandanimalusage
Drivers•UpsurgeintheoutsourcingofR&Dactivities•IncreasingexpenditureonR&D
Market dynamics
Discoveryanddevelopmentservicesinrarediseasesandorphandrugsareexpectedtoincreaseaspharmaceuticalcompaniesarefocusingmoreonthesecomplexareastolaunchnewproductsandservices.CAGR of 11.7%: 2019–2025
CAGR >15%
The industry generates the majority of the revenue from the key players operating
in this field; few of them include Charles River Laboratories, Evotec SE, GVK
Biosciences, Albany Molecular Research Inc., Domainex Ltd., Genscript Biotech
Corporation, Syngene International Ltd., Eurofins Scientific SE, and Laboratory
Corporation of America Holdings.
According to the Infoholic Research analysis, North America accounted for the
largest share of the global drug discovery services market in 2018 and will retain a
high position during the forecast period. North America is followed by Europe, with
a share of more than 25% of the global market in 2018.
By Type:
ï‚· Medicinal Chemistry Services
ï‚· Biology Services
ï‚· Pharmacokinetics and Drug Metabolism
In 2018, the medicinal chemistry services segment accounted for the largest share
and is expected to grow at a high-double-digit CAGR during the forecast period.
Increasing tendency of pharma companies to externalize discovery and
development services, increasing number of drug discovery and development
activities, and growing R&D expenditure are the key factors driving the growth of
the medicinal chemistry services segment. The biology services segment is
projected to grow at a high CAGR during the forecast period 2019–2025.
By Drug Type:
ï‚· Small Molecules
ï‚· Biologics
The small molecules segment occupied a significant share in 2018, and biologics is
expected to grow at a high CAGR during the forecast period 2019–2025. The
increasing use of small molecules drugs to treat chronic disease is leading to
increased demand for these drugs.
By Therapeutic Area:
ï‚· Neurological Disorder
ï‚· Diabetes
ï‚· Oncology
ï‚· Respiratory Disease
ï‚· Cardiovascular Disease
ï‚· Others
Based on therapeutic areas, oncology dominated the market in 2018 and is
expected to maintain its position throughout the forecast period. The high demand
for cancer therapies due to the increasing number of cancer cases across the globe
makes the segment a dominant shareholder in the coming years.
By Regions:
ï‚· North America
ï‚· Europe
ï‚· Asia Pacific
ï‚· Rest of the World
Based on geography, North America dominated the market in 2018 with a market
share of over 40% and is expected to maintain this position throughout the forecast
period. Increasing demand for personalized medicine, well-established healthcare
sector, rising incidence of chronic disease, availability of advanced technologies,
high healthcare expenditure, and rising growth of the biopharmaceutical market are
few of the factors that make North America a dominant shareholder in the global
drug discovery services market. Asia Pacific is projected to grow at the fastest rate
during the forecast period 2019–2025.
Global Drug Discovery Services Market Research Competitive Analysis: The
market is growing at a steady rate with a CAGR of 11.7% during the forecast period
2019–2025. The increasing burden of disease and the need for new therapeutic
drugs have led to an increase in collaboration between companies for drug
discovery services. For instance, in September 2019, German-based Evotec entered
into a multi-year drug discovery collaboration agreement with Japanese pharma
company Takeda Pharmaceutical Company Limited. According to the collaboration
terms, Evotec will leverage its technology platform to establish five drug discovery
programs in the field of oncology, neuroscience, gastroenterology, and rare
diseases, which Takeda will advance into clinical development.
East Midlands’ life sciences researchers and GSK entered into a strategic research
collaboration for lung disease in February 2018, and the partnership is expected to
accelerate discovery and development of innovative treatments
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10325826 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
